Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease Among Adults With HIV—United States, 2008–2018
暂无分享,去创建一个
W. Schaffner | L. Harrison | M. Farley | A. Thomas | Jianmin Li | L. McGee | W. Adih | T. Pilishvili | S. Petit | N. Alden | J. Baumbach | O. Almendares | R. Gierke | Corinne Holtzman | Almea Matanock | A. Reingold | Wei Xing | Miwako Kobayashi | M. Kobayashi | Almea M Matanock | C. Holtzman
[1] R. Lynfield,et al. Invasive pneumococcal strain distributions and isolate clusters associated with persons experiencing homelessness during 2018. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] L. McGee,et al. Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico. , 2020, The Journal of infectious diseases.
[3] W. Schaffner,et al. Early Impact of 13-valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease among Adults with and without Underlying Medical Conditions-United States. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] Miwako Kobayashi,et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.
[5] D. Swerdlow,et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. , 2019, Vaccine.
[6] N. Andrews,et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018. , 2019, Vaccine.
[7] Kenneth J. Smith,et al. Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S. , 2019, Journal of the National Medical Association.
[8] N. Andrews,et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. , 2018, The Lancet. Infectious diseases.
[9] N. Crepaz,et al. Racial and Ethnic Disparities in Sustained Viral Suppression and Transmission Risk Potential Among Persons Receiving HIV Care — United States, 2014 , 2018, MMWR. Morbidity and mortality weekly report.
[10] Ronald Anderson,et al. HIV-related pneumococcal disease prevention in adults , 2017, Expert review of respiratory medicine.
[11] H. Bradley,et al. Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection , 2016, AIDS.
[12] Laila N. Abudulai,et al. Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy , 2016, Journal of acquired immune deficiency syndromes.
[13] W. Schaffner,et al. Twenty Years of Active Bacterial Core Surveillance , 2015, Emerging infectious diseases.
[14] W. Schaffner,et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. , 2015, The Lancet. Infectious diseases.
[15] I. Ssinabulya,et al. Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. , 2014, Immunology letters.
[16] C. Whitney,et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.
[17] W. Schaffner,et al. Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] M. Farley,et al. Socioeconomic and Racial Disparities of Pediatric Invasive Pneumococcal Disease After the Introduction of the 7-valent Pneumococcal Conjugate Vaccine , 2014, The Pediatric infectious disease journal.
[19] Jeffrey N. Martin,et al. Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease , 2014, PloS one.
[20] D. Cooper,et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. , 2011, Vaccine.
[21] Irene Hall,et al. HIV surveillance--United States, 1981-2008. , 2011, MMWR. Morbidity and mortality weekly report.
[22] C. Whitney,et al. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[23] W. Schaffner,et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization , 2010, AIDS.
[24] C. Whitney,et al. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). , 2010, MMWR. Morbidity and mortality weekly report.
[25] Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Morbidity and mortality weekly report.
[26] W. Schaffner,et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.
[27] Richard D Moore,et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003 , 2006, AIDS.
[28] W. Schaffner,et al. Changes in Invasive Pneumococcal Disease among HIV-Infected Adults Living in the Era of Childhood Pneumococcal Immunization , 2006, Annals of Internal Medicine.
[29] Tamara Pilishvili,et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.
[30] A. Schuchat,et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. , 2005, The Journal of infectious diseases.
[31] Steven Black,et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.
[32] J. Ward,et al. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] K. Jenpanich,et al. [Drug administration]. , 1976, Thai journal of nursing.